32 results about "Tail suspension test" patented technology

The invention discloses an antidepressant drug which takes salvianolic acid B as a raw material and the dose thereof. The invention further discloses a preparation method of the drug. Experiments prove that the drug can significantly reduce the immobility time of the tail suspension test and the forced swimming test of tested mice, thereby inferring that the drug has the effect of anti-experimental depression.

The invention relates to a novel chalcone compound Chalcone-1203, and also relates to a preparation method for the compound, a composition using the compound as an active component and application of the compound in preparation of an antidepressant drug. The novel chalcone compound Chalcone-1203 provided by the invention has substantial anti-depression effect. Results of animal testing in the embodiments show that Chalcone-1203 can substantially reduce immobility time of mice in forced swimming test and tail suspension test of the mice, has fast action and small toxic and side effect (TD50>2000 mg / kg), is suitable for long-term usage and shows valuable antidepressant pharmacological properties. The novel chalcone compound uses widely-available and cheap raw materials, is simple to prepare and can be used for preparation of antidepressant drugs of a variety of dosage forms.

The invention discloses application of licorisoflavan A in preparation of drugs for treating depression. Licorisoflavan A is a flavonoid compound separated from a Chinese herb, namely radix glycyrrhizae; the immobilization time of a mouse forced swimming test and tail suspension test of a chronic unpredictable mild stress depression model can be obviously shortened, it is indicated that licorisoflavan A has an excellent anti-depression effect, and by regulating and controlling AMPA receptors, a BDNF-TrkB passage can be adjusted to achieve the anti-depression effect. Licorisoflavan A can be combined with auxiliary agents, used for preparing the drugs for treating depression and applied with other anti-depression drugs.

The invention provides application of coniferyl ferulate to preparing antidepressant drugs, and relates to the field of medicine. The application has the advantages that as proved by in-vitro activity tests, the coniferyl ferulate is excellent in protection activity for PC12 cells injured by corticosterone and glutamic acid; as shown by results of in-vivo tests, the immobility time of mice in forced swimming and tail suspension tests can be obviously shortened by the coniferyl ferulate; as proved by tests, obvious antidepressant effects can be realized by the coniferyl ferulate, and accordingly the coniferyl ferulate can be used for preparing the drugs for preventing and treating depression.

The invention provides new application of sea-buckthorn seed oil extracted from sea-buckthorn seeds, i.e., application of the sea-buckthorn seed oil to preparation of a medicament or a health-care food for preventing and / or treating depression, and application of the sea-buckthorn seed oil serving as a raw material to preparation of the medicament or the health-care food for preventing and / or treating the depression. Test results prove that the immobility time in forced swimming tests of mice and tail suspension tests of the mice can be obviously reduced by the sea-buckthorn seed oil and the sea-buckthorn seed oil has an obvious depression suppression effect. The sea-buckthorn seed oil is a natural anti-depression effective substance which has the advantages of easiness and convenience in preparation, obvious effect, safety, reliability and easiness for industrial production. The sea-buckthorn seed oil can be prepared into formulations such as soft capsules, dropping pills and emulsion for anti-depression medicaments or health care foods.

The tail suspension test apparatus for detecting a struggling state of an animal by suspending a tail of the animal includes an optical mouse, an opaque piece located within a sensing range of the optical mouse, and a fixing device connected with the opaque piece for fixing the tail of the animal. When the animal is struggling, an action of the opaque piece is induced and detected by the optical mouse.

The invention relates to the technology of pharmacy, and particularly relates to application of oridonin in preparation of anti-depression medicines. The anti-depression medicinal ingredient of the anti-depression medicine provided by the invention is oridonin, and has an efficacy dosage 0.01-30mg oridonin per kilogram of the body weight; and an anti-depression effect can be generated in 60 minutes after the medicine is administrated. The medicine has the advantages of remarkable anti-depression effect, quick response, small dosage, small side effect and the like. In a mammal mouse tail suspension test, the oridonin has a more remarkable anti-depression effect than that of conventional anti-depression medicine imipramine, and is expected to become a novel quick and efficient anti-depression medicine without toxic or side effect.

The invention provides the application of coniferyl ferulate in the preparation of antidepressant drugs, and relates to the field of medicine. The present invention proves that coniferyl ferulate has good protective activity on PC12 cells damaged by corticosterone and glutamate through in vitro activity test; in vivo test results show that coniferyl ferulate can significantly shorten the forced swimming and tail suspension tests of mice immobility time. Experiments have proved that coniferyl ferulate has significant antidepressant effect, and can be used to prepare medicines for preventing and treating depression.

The invention provides application of atractylenolide in preparation of an antidepressant drug, and relates to the field of medicine. In-vitro activity tests prove that atractylenolide I and atractylenolide III have the better protection activity on corticosterone-damaged PC12 cells, and the mechanism is related to inhibition of neuron apoptosis; in-vivo test results show that atractylenolide I and atractylenolide III can significantly shorten the immobility time of a mouse forced swimming test and a mouse tail suspension test. Experiments prove that atractylenolide I and atractylenolide III have the significant antidepressant effect and can be used for preparing the drug for preventing and treating a depressive disorder.

The invention discloses application of licorisoflavan A in preparation of drugs for treating depression. Licorisoflavan A is a flavonoid compound separated from a Chinese herb, namely radix glycyrrhizae; the immobilization time of a mouse forced swimming test and tail suspension test of a chronic unpredictable mild stress depression model can be obviously shortened, it is indicated that licorisoflavan A has an excellent anti-depression effect, and by regulating and controlling AMPA receptors, a BDNF-TrkB passage can be adjusted to achieve the anti-depression effect. Licorisoflavan A can be combined with auxiliary agents, used for preparing the drugs for treating depression and applied with other anti-depression drugs.

The invention relates to the field of medicines, and in particular to the application of meptazinol. According to the application of the meptazinol disclosed by the invention, the experiment indicatesthat the meptazinol can achieve the effect of resisting depression through raising the level of Ahi1. Depression resisting model mice are constructed through chronic stress, and then the changes of Ahi1 protein are observed; and the result shows that after 21-day continuous space behavior limit is given to the mice, the depression sample ethology change of the mice is detected through a tail suspension test and a forced swimming test. After the model is successfully constructed, the mice are subjected to intraperitoneal injection according to the dosage of 10mg / kg, physiological saline (NS) is given to the control group, at the same time, space behavior limit is continuously performed each day, the medicine administration time is 12 o'clock at noon and medicine administration is performedfor two weeks continuously; then the depression sample ethology change of the mice is detected by the tail suspension test and the forced swimming test; and then through detection by a Western Blot method, the inventor finds that compared with the Ahi1 protein level of hippocampus of a medicine administration group, the Ahi1 protein level of hippocampus of the depression model mice is notably reduced.